Incyte EVP executes option exercise-and-sell under 10b5-1 plan
Rhea-AI Filing Summary
Sheila A. Denton, EVP & General Counsel of Incyte Corp. (INCY), reported insider option activity under a written trading plan. The report shows Denton exercised 277 employee stock options with a $64.25 exercise price and simultaneously sold 277 shares at $86.81, leaving her beneficial ownership around 33,200 shares when including unvested restricted stock and performance units. The filing indicates an affirmative-defense trading plan consistent with Rule 10b5-1 and discloses remaining employee option holdings that become exercisable/vest under previously reported schedules.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider option exercise and sale under a 10b5-1 plan; small net change in beneficial ownership.
The transaction reflects an executive exercising 277 options at a $64.25 strike and selling the same number of shares at $86.81, a simple exercise-and-sell that realized the spread. Beneficial ownership after the trades is reported at ~33,200 shares, which includes a material amount (32,544 shares) of unvested restricted stock units and performance units. On its face this is routine compensation-related activity rather than a strategic corporate event; it does not alter the company capital structure materially.
TL;DR: Disclosure follows Section 16 and notes a 10b5-1 trading plan; no governance red flags apparent from the filing.
The form is filed by the reporting person through an attorney-in-fact and explicitly checks that the trade was made pursuant to a written plan intended to satisfy Rule 10b5-1(c). The filing also explains the composition of shares that remain subject to vesting and the installment vesting schedule for earlier option grants. There are no indications of undisclosed related-party transactions or departures from standard Section 16 reporting practices.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 277 | $0.00 | -- |
| Exercise | Common Stock | 277 | $64.25 | $18K |
| Sale | Common Stock | 277 | $86.81 | $24K |
Footnotes (1)
- This includes an aggregate of 32,544 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested. The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.